Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock

Reuters

07-28

Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock

Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554702687"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554702687\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2554702687?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554702687","market":"nz","top_or_hot":-1,"title":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IBO\">Impact Biomedical</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImpact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-28 23:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IBO\">Impact Biomedical</a> Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBO","symbol_name":"Impact Biomedical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLlyJpC:1","article_id":"2554702687","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554702687","pubTimestamp":1753715168,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock. Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBO":"Impact Biomedical, Inc.","BK4007":"制药","DSS":"DSS Inc","BK4563":"昨日强势股","BK4087":"商业印刷","AEI":"Alset EHome International Inc.","BK4024":"房地产开发"},"translate_title":"Impact BioMedical Inc.宣布债务转换协议，通过发行普通股与DSS，Inc.解决1200万美元贷款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEI":0.9,"DSS":0.9,"IBO":0.9},"content_text":"Impact BioMedical Inc. Announces Debt Conversion Agreement to Settle $12 Million Loan with DSS, Inc. Through Issuance of Common Stock\n    \n\n        Impact BioMedical Inc. has announced a significant financial restructuring through a Debt Conversion Agreement with DSS, Inc. The agreement involves the conversion of an outstanding loan, originally valued at $12 million, into common stock. Under the terms of the agreement, Impact BioMedical will issue 31,939,778 shares of its common stock to DSS, effectively settling the debt in full. The original loan, which was subject to amendments including a revised interest rate of WSJ Prime + 0.5%, will be entirely satisfied with this conversion. This strategic move aims to strengthen Impact BioMedical's financial position by reducing its debt obligations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021085), on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}